Mumbai, July 6 -- The company said the product is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa IntraMuscular Injection 10 mg/vial, marketed by Cheplapharm Registration GmbH under NDA 021253.

According to IQVIA sales data for the 12-month period ended May 2026, the reference product recorded annual sales of approximately $25.4 million in the US.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectable portfolio and strengthening our presence within the institutional channel. It reflects our continued commitment to expanding access to quality and affordable treatment opt...